|1.||Yin, Yong-Qin: 2 articles (01/2010 - 08/2009)|
|2.||Shen, Zhi-Bin: 2 articles (01/2010 - 08/2009)|
|3.||Chen, Chao: 2 articles (01/2010 - 08/2009)|
|4.||Tang, Chun-Ping: 2 articles (01/2010 - 08/2009)|
|5.||Zhu, Shu-Bing: 1 article (12/2012)|
|6.||Dong, Zhi: 1 article (12/2012)|
|7.||Sun, Hua-Fu: 1 article (12/2012)|
|8.||Yang, Yan-Ying: 1 article (12/2012)|
|9.||Yang, Mei-Ping: 1 article (12/2012)|
|10.||Yan, Chao-Yan: 1 article (01/2010)|
12/01/2012 - "The ratio between the serious ADR of proprietary Chinese medicines and the safety risk of non-proprietary Chinese medicines was 1.057 (95% CI:0.915, 1. 221), suggesting that the safety of proprietary Chinese medicines was not higher than the non-proprietary Chinese; as such medicines as Qingkailing, Xuesaitong and Xiangdan have ranked top five for years in terms of ADR and serious ADR, the drug administration and hygiene system shall take more effective control measures for strengthening the monitoring over rational use of drugs; clinical manifestations of severe ADR of proprietary Chinese medicines were dominated by allergic shock, which could not be effectively prevented and monitored by such means as skin test, therefore, pre-clinical treatment risk-benefit evaluation shall be improved."
01/08/2010 - "Pharmacodynamic screening and simulation study of anti-hypoxia active fraction of xiangdan injection."
08/01/2009 - "[Simulation study of anti-hypoxia active fraction of Xiangdan injection by support vector machine]."
01/08/2010 - "The anti-hypoxia active fraction of Xiangdan injection was determined by experiments. "
01/08/2010 - "To investigate the anti-hypoxia active fraction of Xiangdan injection. "
08/01/2009 - "Moreover, the anti-hypoxia active fraction of Xiangdan injection was determined by experimental confirmation. "
|4.||Coronary Disease (Coronary Heart Disease)
03/01/2004 - "Fifty-six patients were randomly divided into two groups:twenty-eight patients were treated according to the therapeutic guide for coronary heart disease as the control group and 28 were given the same treatment plus Xiangdan Injection as the treated group. "
03/01/2004 - "Xiangdan Injection improves the endothelial function of patients with coronary heart disease and blood stasis by regulating the expressions of ET-1 and eNOS mRNA."
03/01/2004 - "To evaluate the effect of Xiangdan Injection on mRNA expression of the endothelial vaso-active factors of patients with coronary heart disease and blood stasis. "
03/01/2004 - "[Effect of Xiangdan Injection on mRNA expression of endothelial vaso-active factors of patients with coronary heart disease and blood stasis]."
|2.||Messenger RNA (mRNA)
|1.||Chinese Traditional Medicine (Traditional Chinese Medicine)